AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...

Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction benefit with AtriClip devices for the over one million cardiac surgery ...

The left atrial appendage (LAA) is a significant source of strokes in patients with atrial fibrillation (AF). Helena Dominguez from the Department of Cardiology at the University of Copenhagen ...

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (ATRC) (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, ...

AtriCure (Nasdaq: ATRC) + today announced the first use of its newest AtriClip device for minimally invasive concomitant procedures. Doctors used the AtriClip PRO-Mini left atrial appendage (LAA) ...

AtriCure, Inc. is a market leader in surgical solutions for atrial fibrillation, LAA management, and post-operative pain management, serving 2,000 hospitals globally. AtriCure's latest project ...

AtriCure, Inc. ATRC recently announced receipt of regulatory approval from China’s National Medical Products Administration (NMPA) for its AtriClip Left Atrial Appendage (LAA) Exclusion System. This ...

Credit: Patrick J. Lynch, medical illustrator; C. Carl Jaffe, MD, cardiologist. Adjunctive left atrial appendage (LAA) ligation failed to increase the efficacy of catheter pulmonary vein isolation ...